Helicobacter Infection Clinical Trial
Official title:
Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection
This study is conducted to investigate whether the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin 1 g and clarithromycin 500 mg for 14 days in the treatment of H pylori infection.
Multiple regimens have been evaluated for H. pylori therapy in randomized controlled trials
The treatment regimen that is selected must be effective, but considerations such as cost,
side effects, and ease of administration should also be taken into account. Despite the
number of studies, the optimal therapeutic regimen has not yet been defined.
The regimen most commonly recommended for first line treatment of H. pylori is triple
therapy with a PPI, amoxicillin and clarithromycin for 14 days. However, the multi-drug
application is associated with remarkable side effects and it is not uncommon not to be able
to complete a treatment course. Thus, treatment failure is associated with H. pylori strains
that are resistant to the commonly used antibiotics. This study is conducted to investigate
whether the efficacy of single-dose triple therapy (Esomeprazole 40 mg, Tinidazole 1 g, and
Levofluxacine 500 mg) for 14 days is superior to double-dose lansoprazole 30 mg, amoxicillin
1 g and clarithromycin 500 mg for 14 days in the treatment of H pylori infection.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00656968 -
Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection
|
Phase 4 | |
| Completed |
NCT00841854 -
Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication
|
Phase 4 | |
| Completed |
NCT02051348 -
Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion
|
Phase 2/Phase 3 | |
| Completed |
NCT02349685 -
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
|
N/A | |
| Recruiting |
NCT01723059 -
Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection
|
N/A | |
| Recruiting |
NCT02373280 -
The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection
|
N/A | |
| Terminated |
NCT02359331 -
The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection
|
N/A | |
| Completed |
NCT01163435 -
Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication
|
Phase 4 |